Transgene Reports Business Update and Q3 2023 Financial Position
Revenue from collaborative and licensing agreements amounted to €1.2 million in the first nine months of 2023, compared with €3 million in the same period in 2022.
- Revenue from collaborative and licensing agreements amounted to €1.2 million in the first nine months of 2023, compared with €3 million in the same period in 2022.
- In the first half of 2023, AstraZeneca informed Transgene of its decision to end the collaboration.
- Cash, cash equivalents and other financial assets stood at €16.4 million as of September 30, 2023, compared to €26.8 million as of December 31, 2022.
- On September 20, 2023, the Company signed a current account advance agreement with Institut Mérieux (TSGH) for a maximum of €36 million.